Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28555380 | 0.87 | ALDH1A1 (0.38) | PTGDR2ALDH1A1CXCR1CXCR2USP2 | |
| SCHEMBL3364010 | 0.83 | USP2 (0.39) | PTGDR2ALDH1A1USP2KMT2AMEN1 | |
| SCHEMBL1397132 | 0.79 | FABP7 (0.40) | PTGDR2CYP19A1KMT2AMEN1KDM4E | |
| SCHEMBL1397178 | 0.78 | PTGDR2 (0.40) | PTGDR2ALDH1A1USP2HPGDLMNA | |
| SCHEMBL2197295 | 0.78 | CYP19A1 (0.46) | PTGDR2ALDH1A1CYP19A1USP2HPGD | |
| SCHEMBL4415633 | 0.77 | HPGD (0.49) | ALDH1A1HPGDKMT2AKDM4EHSD17B10 | |
| SCHEMBL6655190 | 0.77 | ALDH1A1 (0.68) | PTGDR2ALDH1A1CYP19A1KMT2AMEN1 | |
| SCHEMBL6774389 | 0.77 | RAB9A (0.49) | ALDH1A1CXCR1CXCR2CYP19A1KMT2A | |
| SCHEMBL24589208 | 0.76 | CYP19A1 (0.38) | PTGDR2ALDH1A1CXCR1CXCR2CYP19A1 | |
| SCHEMBL21883683 | 0.76 | ALDH1A1 (0.49) | PTGDR2ALDH1A1CXCR1CXCR2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| EP-1595182-B1 | HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | BASF SE (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2349993-B1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2349993-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2288599-A1 | SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | BASF SE (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2197839-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197840-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197869-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1472576-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004074242-A2 | HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-09-02 | — | — | WO | disclosed |
| EP-1392675-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1344109-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002098870-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002046507-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| US-6261738-B1 | LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | PTGDR2 2315/4885ALDH1A1 217/4885CXCR1 487/4885 |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | NR2E3, HCAR3, HRH4 | PTGDR2 1186/4885ALDH1A1 1482/4885CXCR1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.